Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis

作者：Zhang, Yinlong; Wei, Jingyan^*; Liu, Shaoli; Wang, Jing; Han, Xuexiang; Qin, Hao; Lang, Jiayan; Cheng, Keman; Li, Yiye; Qi, Yingqiu; Anderson, Greg J.; Sukumar, Saraswati; Li, Suping^*; Nie, Guangjun^*

来源：Theranostics, 2017, 7(5): 1062-1071.

DOI：10.7150/thno.17908

• Tumor associated platelets
• tumor metastasis
• liposomal nanoparticle
• metastatic inhibition

Extensive evidence has shown that platelets support tumor metastatic progression by inducing epithelial-mesenchymal transition of cancer cells and by shielding circulating tumor cells from immune-mediated elimination. Therefore, blocking platelet function represents a potential new avenue for therapy focused on eliminating metastasis. Here we show that liposomal nanoparticles bearing the tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) can deliver a platelet inhibitor, ticagrelor, into tumor tissues to specifically inhibit tumor-associated platelets. The drug-loaded nanoparticles (CREKA-Lipo-T) efficiently blocked the platelet-induced acquisition of an invasive phenotype by tumor cells and inhibited platelet-tumor cell interaction in vitro. Intravenously administered CREKA-Lipo-T effectively targeted tumors within 24 h, and inhibited tumor metastasis without overt side effects. Thus, the CREKA-Lipo formulation provides a simple strategy for the efficient delivery of anti-metastatic drugs and shows considerable promise as a platform for novel cancer therapeutics.

• 单位
  中国科学院; 国家纳米科学中心; 厦门大学; 吉林大学; 中国科学院大学